[Skip to Content]
[Skip to Content Landing]
November 1, 1965


JAMA. 1965;194(5):552-553. doi:10.1001/jama.1965.03090180076019

Most drugs can move freely in interstate channels of commerce. Increasing mobility and turnover in population means that the consuming public, medical practitioners, pharmacists, and others in the chain of distribution buy, sell, or dispense drugs today in one state and tomorrow in another. They, together with health officials and enforcement officers, are thus confronted with the need for keeping abreast of and complying with changes in local, state, and federal laws, and must constantly reeducate the public and themselves. Nowhere is this more evident than in the control of therapeutic narcotic drug products.

The manufacture and distribution of medicinal narcotics are surrounded by exceptional federal safeguards based upon many years of American and world experience. Exempt (nonprescription) status, as well as each prescription classification of narcotic drug products, is based on medical utility, safety, addiction liability, and other significant characteristics. Such status is recommended by a number of national

First Page Preview View Large
First page PDF preview
First page PDF preview